Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Isofol Medical AB's Enterprise Value is kr158.47 Mil.
Isofol Medical AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr-55.58 Mil. Therefore, Isofol Medical AB's EV-to-OCF for today is -2.85.
The historical rank and industry rank for Isofol Medical AB's EV-to-OCF or its related term are showing as below:
OSTO:ISOFOL'
s EV-to-OCF Range Over the Past 10 Years
Min: -15.11 Med: -3.65 Max: 2.88
Current: -2.85
During the past 11 years, the highest EV-to-OCF of Isofol Medical AB was 2.88. The lowest was -15.11. And the median was -3.65.
OSTO:ISOFOL's EV-to-OCF is ranked worse than 55.29% of 1409
companies
in the Biotechnology industry
Industry Median: -3.71
vs OSTO:ISOFOL: -2.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Isofol Medical AB (OSTO:ISOFOL) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Isofol Medical AB's PE Ratio (TTM) for today is calculated as:
Isofol Medical AB's share price for today is kr0.84.
Isofol Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Isofol Medical AB EV-to-OCF Related Terms
Isofol Medical AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Isofol Medical AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ISOFOL vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Isofol Medical AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Isofol Medical AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Isofol Medical AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Isofol Medical AB's EV-to-OCF falls into.
Isofol Medical AB's current Enterprise Value is kr158.47 Mil.
Isofol Medical AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-55.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Isofol Medical AB (OSTO:ISOFOL) has a EV-to-OCF of -2.85 as of Aug. 26, 2026. According to the industry distribution chart, Isofol Medical AB ranks #779 out of 1409 companies in the Biotechnology industry, placing it in the top 55.3%.
Is Isofol Medical AB's EV-to-OCF too high?
Isofol Medical AB's current EV-to-OCF is -2.85. Based on the distribution chart, Isofol Medical AB ranks #779 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Isofol Medical AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Isofol Medical AB ranks #779 out of 1409 companies for EV-to-OCF. This places Isofol Medical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Isofol Medical AB's current EV-to-OCF is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current EV-to-OCF of -2.85. The current EV-to-OCF is -2.85. Isofol Medical AB's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current EV-to-OCF is -2.85 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
24GF Score
Get the complete analysis for OSTO:ISOFOL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ISOFOL has been successfully added to your 
